Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02051868




Registration number
NCT02051868
Ethics application status
Date submitted
13/01/2014
Date registered
31/01/2014
Date last updated
4/11/2015

Titles & IDs
Public title
International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel
Scientific title
An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease
Secondary ID [1] 0 0
2013-001949-13
Secondary ID [2] 0 0
CCR 3847 InterAACT
Universal Trial Number (UTN)
Trial acronym
InterAACT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Squamous Cell Carcinoma of the Anus 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Bowel - Anal

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cisplatin
Treatment: Drugs - 5-Fluorouracil (5-FU)
Treatment: Drugs - Carboplatin
Treatment: Drugs - Paclitaxel

Active comparator: Arm A - Cisplatin and 5-Fluorouracil

Experimental: Arm B - Carboplatin plus Paclitaxel


Treatment: Drugs: Cisplatin
Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.

Treatment: Drugs: 5-Fluorouracil (5-FU)
5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.

Treatment: Drugs: Carboplatin
Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.

Treatment: Drugs: Paclitaxel
Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Best overall response rate by 24 weeks post treatment
Timepoint [1] 0 0
24 weeks
Secondary outcome [1] 0 0
Feasibility of conducting a multicentre, international study on squamous cell carcinoma of the anus and recruiting within a reasonable time frame.
Timepoint [1] 0 0
3 years
Secondary outcome [2] 0 0
Toxicity
Timepoint [2] 0 0
Toxicity will be analysed once all patients have been followed up for at least 4 weeks post treatment.
Secondary outcome [3] 0 0
Progression-free survival
Timepoint [3] 0 0
PFS will be analysed once all patients have been followed up for at least 12 months post treatment.
Secondary outcome [4] 0 0
Overall survival
Timepoint [4] 0 0
Overall survival will be analysed once all patients have been followed up for at least 12 months post treatment.
Secondary outcome [5] 0 0
Disease control rate
Timepoint [5] 0 0
12 and 24 weeks post treatment start
Secondary outcome [6] 0 0
Best overall response rate of non-irradiated lesions
Timepoint [6] 0 0
24 weeks post treatment start
Secondary outcome [7] 0 0
Anti-tumour activity and magnitude of tumour response
Timepoint [7] 0 0
24 weeks
Secondary outcome [8] 0 0
Quality of Life
Timepoint [8] 0 0
3 years
Secondary outcome [9] 0 0
Identification of potential tumour biomarker
Timepoint [9] 0 0
3 years

Eligibility
Key inclusion criteria
Inclusion Criteria

1. Histologically or cytologically verified, uni-dimensionally measurable, inoperable, locally recurrent or metastatic squamous cell carcinoma of the anus.
2. Age =18 years.
3. ECOG Performance status =2.
4. Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1.
5. Previous definitive chemoradiotherapy is permitted for early stage squamous cell carcinoma of the anus.
6. HIV+ patients will be considered eligible with a CD4 count of =200.
7. Adequate cardiac and respiratory function; absolute neutrophil count (ANC) =1.5x10^9/l; white blood cell (WBC) count =3x10^9/l; platelets >100x10^9/l; haemoglobin (Hb) =9g/dl; creatinine clearance >50ml/minute; serum bilirubin =1.5x upper limit of normal (ULN); alanine transaminase (ALT)/aspartate transaminase (AST) =2.5x ULN; alkaline phosphatase (ALP) =3x ULN.
8. Fertile men and women must agree to take adequate contraceptive precautions during, and for at least six months after therapy.
9. Life expectancy of at least 3 months.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

1. Tumours of adenocarcinoma, melanoma, small cell and basal cell histology are excluded.
2. Previous chemotherapy, radiotherapy or other investigational drug for surgically unresectable locally recurrent or advanced squamous cell carcinoma of the anus
3. Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study.
4. Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease.
5. Surgery or palliative radiotherapy within 28 days of randomisation.
6. Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery disease, uncontrolled cardiac arrhythmia, or myocardial infarction within the last 6 months). Any history of clinically significant cardiac failure.
7. History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan.
8. Lack of physical integrity of the gastro-intestinal tract, malabsorption syndrome (naso-gastric or jejunostomy feeding tube is permitted).
9. Acute hepatitis C and/or chronic active hepatitis B infection.
10. Serious active infection requiring i.v. antibiotics at enrolment.
11. Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
12. Other clinically significant disease or co-morbidity that may adversely affect the safe delivery of treatment within this trial.
13. Known hypersensitivity to any of the study drugs or excipients.
14. Known peripheral neuropathy = grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible).
15. Pre-existing hearing impairment.
16. Patients planning for a live vaccine.
17. Pregnant or lactating females.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/02/2018
Actual
Sample size
Target
80
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Margot Gorzeman - Sydney
Recruitment postcode(s) [1] 0 0
NSW 1450 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Massachusetts
Country [2] 0 0
United Kingdom
State/province [2] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Other
Name
Royal Marsden NHS Foundation Trust
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Cancer Research UK
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Australasian Gastro-Intestinal Trials Group
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
ECOG-ACRIN Cancer Research Group
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
European Organisation for Research and Treatment of Cancer - EORTC
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
International Rare Cancers Initiative (IRCI ) This study is indorsed by IRCI
Address [5] 0 0
Country [5] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sheela Rao, MD, FRCP
Address 0 0
Royal Marsden NHS Foundation Trust
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Sheela Rao, MD, FRCP
Address 0 0
Country 0 0
Phone 0 0
+44 (0) 0208 642 6011
Fax 0 0
Email 0 0
sheela.rao@rmh.nhs.uk
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT02051868